References
- Montané E, Ibáñez L, Vidal X, et al. Epidemiology of aplastic anemia: a prospective multicenter study. Haematologica. 2008;93(4):518–523. doi:10.3324/haematol.1202018322256
- Young NS, Kaufman DW. The epidemiology of acquired aplastic anemia. Haematologica. 2008;93(4):489–492. doi:10.3324/haematol.1285518379007
- Aplastic Anemia. Aplastic anemia & MDS international foundation. Available from: https://www.aamds.org/diseases/aplastic-anemia Accessed 9 12, 2019.
- Brodsky RA, Jones RJ. Aplastic anaemia. Lancet Lond Engl. 2005;365(9471):1647–1656. doi:10.1016/S0140-6736(05)66515-4
- Aplastic Anemia | National Heart, Lung, and Blood Institute (NHLBI). Available from: https://www.nhlbi.nih.gov/health-topics/aplastic-anemia Accessed 912, 2019.
- Peffault De Latour R, Huynh L, Ivanova JI, et al. A retrospective chart review to assess burden of illness among patients with severe aplastic anemia with insufficient response to immunosuppressive therapy. Blood. 2017;130(Suppl 1):678.
- Sureda A, Bader P, Cesaro S, et al. Indications for allo- and auto-SCT for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2015. Bone Marrow Transplant. 2015;50(8):1037–1056. doi:10.1038/bmt.2015.625798672
- Killick SB, Bown N, Cavenagh J, et al. Guidelines for the diagnosis and management of adult aplastic anaemia. Br J Haematol. 2016;172(2):187–207. doi:10.1111/bjh.1385326568159
- Heublein S, Wehner F, Höchsmann B, Hochhaus A, Hartmann M, La Rosée P. Modelling cost effectiveness of horse antithymocyte globulin for treating severe aplastic anaemia in Germany. Ann Hematol. 2013;92(6):825–830. doi:10.1007/s00277-013-1688-223404582
- Marsh JCW, Ball SE, Cavenagh J, et al. Guidelines for the diagnosis and management of aplastic anaemia. Br J Haematol. 2009;147(1):43–70. doi:10.1111/j.1365-2141.2009.07842.x19673883
- Dolberg OJ, Levy Y. Idiopathic aplastic anemia: diagnosis and classification. Autoimmun Rev. 2014;13(4–5):569–573. doi:10.1016/j.autrev.2014.01.01424424170
- Groth M, Singer S, Niedeggen C, et al. Development of a disease-specific quality of life questionnaire for patients with aplastic anemia and/or paroxysmal nocturnal hemoglobinuria (QLQ-AA/PNH)-report on phases I and II. Ann Hematol. 2017;96(2):171–181. doi:10.1007/s00277-016-2867-827837250
- Guinan EC. Diagnosis and management of aplastic anemia. Hematol Am Soc Hematol Educ Program. 2011;2011:76–81. doi:10.1182/asheducation-2011.1.76
- Meehan KR, Matias CO, Rathore SS, et al. Platelet transfusions: utilization and associated costs in a tertiary care hospital. Am J Hematol. 2000;64(4):251–256. doi:10.1002/1096-8652(200008)64:4<251::aid-ajh3>3.0.co;2-n10911376
- Novartis. Promacta US Prescribing Information. NJ: Novartis Pharmaceuticals Corporation; 2019.
- Desmond R, Townsley DM, Dumitriu B, et al. Eltrombopag restores trilineage hematopoiesis in refractory severe aplastic anemia that can be sustained on discontinuation of drug. Blood. 2014;123(12):1818–1825. doi:10.1182/blood-2013-10-53474324345753
- Townsley DM, Scheinberg P, Winkler T, et al. Eltrombopag added to standard immunosuppression for aplastic anemia. N Engl J Med. 2017;376(16):1540–1550. doi:10.1056/NEJMoa161387828423296
- US Department of Labor. U.S. Bureau of Labor Statistics; 2016 https://www.bls.gov/ Accessed 912, 2019.
- Sullivan SD, Mauskopf JA, Augustovski F, et al. Budget impact analysis-principles of good practice: report of the ISPOR 2012 budget impact analysis good practice II task force. Value Health J Int Soc Pharmacoeconomics Outcomes Res. 2014;17(1):5–14. doi:10.1016/j.jval.2013.08.2291
- Huynh L, Ivanova J, Totev T, et al. PSY90 - health resource burden among patients with severe aplastic anemia who have had insufficient response to immunosuppressive therapy: a retrospective chart review study. Value Health. 2018;21:S259–S260. doi:10.1016/j.jval.2018.04.1732
- US Department of Health and Human Services. Healthcare Cost and Utilization Project (HCUP).; 2014 https://www.hcup-us.ahrq.gov/ Accessed 912, 2019.